ClinicalTrials.gg
CompletedNCT02648542Updated Dec 19, 2024

The Effects of Compensatory Auditory Stimulation and Transcranial Direct Current Stimulation on Tinnitus Perception

An interventional study of Compensatory auditory stimulation and transcranial direct current stimulation in Tinnitus, sponsored by Soterix Medical. Completed. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-19.

Sponsored by Soterix Medical · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study evaluates the ability of compensatory auditory stimulation (CAS) and transcranial direct current stimulation (tDCS) to help alleviate tinnitus. Subjects will receive CAS, tDCS, and the combination of the two to assess the effectiveness of the treatment.

Read the detailed description

Tinnitus refers to persistent "ringing in the ears" in absence of external sound. For some individuals tinnitus can be disabling. Most tinnitus is of idiopathic origin and currently there are no reliable treatment options available. Existing approaches, such as hearing aids, counseling, and noise masking typically provide only partial relief and only for a minority of patients. Newer exploratory methods include tailored auditory stimulation and various brain stimulation techniques. While these techniques show great promise in a subset of subjects (maybe about 1/3), it is hard to anticipate which, if any, will benefit a given patient.

Transcranial Direct Current Stimulation (tDCS) has been explored for a number of neurological conditions, and it is most effective when paired with some form of training (e.g. motor rehab after stroke). For tinnitus however this treatment modality has only been tested in isolation. The purpose of this pilot study is to explore the benefits of combining tailored compensatory auditory stimulation with tDCS.

There is widespread consensus in the research community that tinnitus originates with some peripheral hearing deficit, and that maladaptive central plastic mechanisms subsequently lead to the tinnitus percept. Most individuals with tinnitus have audiometric evidence of hearing loss. Our hypothesis is that reduced input to the auditory pathway leads to increased sensitivity (auditory gain) and finally aberrant activity in the frequency band with hearing loss. In this view, auditory stimulation that compensates for the reduced input can potentially revert the maladaptive plasticity.This is consistent with the reported benefits of hearing aids and tailored auditory stimulation. Our hypothesis is that tDCS can boost adaptation induced by compensatory auditory stimulation to reduce the strength of the phantom percept.

02

Conditions studied

  • Tinnitus

Browse trials for

03

In context

Tinnitus

446 studies on the registry are indexed under Tinnitus; 98 are open to participants now.

This study's enrollment of 17 is below the median of 60 across 370 interventional studies indexed under Tinnitus.

Browse Tinnitus studies →

Lead sponsor

Soterix Medical is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 18-80 years of age
  • No history of otological disease
  • Subjects with hearing loss, hyperacusis and/or tinnitus are eligible to participate

Exclusion criteria

Exclusion Criteria:

  • hearing loss greater than 50 dB HL
  • Shows signs of depression or anxiety (Zung self-rating Depression Scale > 50; Beck Anxiety Inventory > 36)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
17 participants (actual)

Study arms

  • Active comparator
    CAS vs. tDCS

    Assess the efficacy of compensatory auditory stimulation (CAS) versus transcranial direct current stimulation (tDCS)

    Other: Compensatory auditory stimulation · Device: transcranial direct current stimulation

  • Sham comparator
    Combined CAS+tDCS vs. Sham

    Assess the efficacy of combined compensatory auditory stimulation (CAS) + transcranial direct current stimulation (tDCS) versus sham stimulation

    Other: Combined CAS and tDCS · Other: Sham stimulation

Interventions

  • OtherCompensatory auditory stimulation

    Compensating for peripheral hearing loss by adjusting sound levels based on individual audiogram.

    Also known as: CAS

  • Devicetranscranial direct current stimulation

    Low-current electrical brain stimulation

    Also known as: tDCS

  • OtherCombined CAS and tDCS

    Combined auditory and electrical stimulation

    Also known as: CAS + tDCS

  • OtherSham stimulation

    Sham stimulation

    Also known as: Sham

06

What researchers measure

Primary outcomes

  1. Reduction in minimum masking levels

    Measurement of the minimum masking level required to mask the subjective tinnitus loudness is assessed after each intervention.

    Time frame: 2 weeks

  2. Reduction in tinnitus percept as assessed via the visual analog test of tinnitus loudness

    Measurement of the subjective loudness of the tinnitus percept is measured using the visual analog scale test after each intervention.

    Time frame: 2 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified data will be shared if requested

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2015
First posted
Jan 7, 2016
Start
Mar 2013
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Last update
Dec 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02648542
Lead sponsor
Soterix Medical
Responsible party
Sponsor
First posted
Jan 7, 2016
Start date
Mar 2013
Primary completion
Jul 2014
Completion
Jul 2014
Last update
Dec 19, 2024

Study contacts

Lucas C Parra, Ph.D.
principal investigator · City College of New York, CUNY

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion